Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Tandem Diabetes to $50 from $45 and keeps an Overweight rating on the shares. Tandem Diabetes delivered an outsized beat in Q1, partly due to Mobi, and raised 2024 guidance by $18M, which is driven by U.S. renewals and OUS new starts, the analyst tells investors in a research note. Wells believes the company’s guidance raise seems conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Wells upgrades Tandem Diabetes on positive endocrinologist survey
- Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
- Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
- Tandem Diabetes upgraded to Outperform from Market Perform at Leerink
- Tandem Diabetes price target raised to $40 from $37 at Stifel